Product Description
CAS:68373-14-8
Sulbactam is a β-lactamase inhibitor. This drug is given in combination with β-lactam antibiotics to inhibit β-lactamase.
Sulbactam acid is intermediate for Sulbactam Sodium.
AI Product Description
*The following content is generated by AI and is for reference only.
Sulbactam acid, chemically known as (2S,5R)-3-(1-hydroxyethyl)-4-azetidinyl-2-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, is a pivotal beta-lactamase inhibitor used extensively in clinical microbiology and pharmaceutical formulations. With the CAS Registry Number 68974-09-2, this compound serves as the active acidic form of sulbactam, a structural analog of penicillin that lacks significant intrinsic antibacterial activity on its own but acts as a potent synergist when combined with beta-lactam antibiotics. Its primary molecular formula is C8H13NO5S, reflecting a complex bicyclic structure containing a strained beta-lactam ring fused to a thiazolidine-like system, which is essential for its mechanism of action.
The fundamental utility of Sulbactam acid lies in its ability to irreversibly bind to and inhibit bacterial beta-lactamases, specifically Class A enzymes produced by resistant strains such as Staphylococcus aureus, Haemophilus influenzae, and certain Enterobacteriaceae. By neutralizing these hydrolytic enzymes, it protects co-administered penicillins like ampicillin or carbapenems from degradation, thereby restoring their efficacy against previously resistant pathogens. This synergy is clinically critical for treating complicated intra-abdominal infections, skin and soft tissue infections, and nosocomial pneumonia where multidrug-resistant organisms are prevalent.
In industrial applications, Sulbactam acid is primarily utilized as an intermediate for synthesizing stable sodium salts, most notably Sodium Sulbactam, which is formulated into injectable solutions. The acid form itself is less soluble in water compared to its salt counterpart, necessitating conversion for parenteral administration. Research continues to explore novel derivatives of Sulbactam acid to combat emerging resistance mechanisms, including extended-spectrum beta-lactamases (ESBLs) and AmpC enzymes. As antibiotic stewardship becomes increasingly vital globally, compounds like Sulbactam acid remain indispensable tools in modern antimicrobial therapy, ensuring that life-saving beta-lactam antibiotics retain their potency against evolving bacterial threats. Its role underscores the importance of combination therapies in overcoming the escalating crisis of antimicrobial resistance worldwide.